Basic principles of intravenous immunoglobulin (IVIg) treatment

@article{citeulike:2606320, abstract = {Abstract \ \ The original rationale for the therapeutic application of immunoglobulins was prevention and treatment of infectious diseases. With the description of agammaglobulinemia, substitution therapy became the primary indication for the use of immunoglobulins. Limitations and side effects of the intramuscular administration of immunoglobulins led to the development of preparations for intravenous use (IVIg). In the early 1980s an immunomodulatory effect of IVIg was described. Since then, the efficacy of IVIg has been established in controlled trials for diseases like idiopathic thrombocytopenic purpura, Kawasaki disease, Guillain-Barr\'{e} syndrome, dermatomyositis, and many others. There is a large body of evidence that IVIg can modulate an immune reaction at the level of T cells, B cells, and macrophages, interferes with antibody production and degradation, modulates the complement cascade, and has effects on the cytokine network. However, the precise mechanism of action is not yet clear.}, author = {Stangel, Martin and Pul, Refik }, citeulike-article-id = {2606320}, doi = {10.1007/s00415-006-5003-1}, journal = {Journal of Neurology}, keywords = {ivig}, number = {0}, pages = {v18--v24}, posted-at = {2008-03-28 13:19:26}, priority = {0}, title = {Basic principles of intravenous immunoglobulin (IVIg) treatment}, url = {http://dx.doi.org/10.1007/s00415-006-5003-1}, volume = {253}, year = {2006} }

TY - JOUR ID - citeulike:2606320 L3 - citeulike-article-id:2606320 TI - Basic principles of intravenous immunoglobulin (IVIg) treatment JF - Journal of Neurology VL - 253 IS - 0 SP - v18 EP - v24 N2 - Abstract   The original rationale for the therapeutic application of immunoglobulins was prevention and treatment of infectious diseases. With the description of agammaglobulinemia, substitution therapy became the primary indication for the use of immunoglobulins. Limitations and side effects of the intramuscular administration of immunoglobulins led to the development of preparations for intravenous use (IVIg). In the early 1980s an immunomodulatory effect of IVIg was described. Since then, the efficacy of IVIg has been established in controlled trials for diseases like idiopathic thrombocytopenic purpura, Kawasaki disease, Guillain-Barré syndrome, dermatomyositis, and many others. There is a large body of evidence that IVIg can modulate an immune reaction at the level of T cells, B cells, and macrophages, interferes with antibody production and degradation, modulates the complement cascade, and has effects on the cytokine network. However, the precise mechanism of action is not yet clear. KW - ivig AU - Stangel, Martin AU - Pul, Refik PY - 2006//29/ UR - http://dx.doi.org/10.1007/s00415-006-5003-1 ER -